1
|
Blinova E, Pakhomov D, Shimanovsky D, Kilmyashkina M, Mazov Y, Demura T, Drozdov V, Blinov D, Deryabina O, Samishina E, Butenko A, Skachilova S, Sokolov A, Vasilkina O, Alkhatatneh BA, Vavilova O, Sukhov A, Shmatok D, Sorokvasha I, Tumutolova O, Lobanova E. Cerium-Containing N-Acetyl-6-Aminohexanoic Acid Formulation Accelerates Wound Reparation in Diabetic Animals. Biomolecules 2021; 11:biom11060834. [PMID: 34205061 PMCID: PMC8230275 DOI: 10.3390/biom11060834] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 05/29/2021] [Accepted: 06/01/2021] [Indexed: 01/05/2023] Open
Abstract
Background: The main goal of our study was to explore the wound-healing property of a novel cerium-containing N-acethyl-6-aminohexanoate acid compound and determine key molecular targets of the compound mode of action in diabetic animals. Methods: Cerium N-acetyl-6-aminohexanoate (laboratory name LHT-8-17) as a 10 mg/mL aquatic spray was used as wound experimental topical therapy. LHT-8-17 toxicity was assessed in human skin epidermal cell culture using (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A linear wound was reproduced in 18 outbred white rats with streptozotocin-induced (60 mg/kg i.p.) diabetes; planar cutaneous defect was modelled in 60 C57Bl6 mice with streptozotocin-induced (200 mg/kg i.p.) diabetes and 90 diabetic db/db mice. Firmness of the forming scar was assessed mechanically. Skin defect covering was histologically evaluated on days 5, 10, 15, and 20. Tissue TNF-α, IL-1β and IL-10 levels were determined by quantitative ELISA. Oxidative stress activity was detected by Fe-induced chemiluminescence. Ki-67 expression and CD34 cell positivity were assessed using immunohistochemistry. FGFR3 gene expression was detected by real-time PCR. LHT-8-17 anti-microbial potency was assessed in wound tissues contaminated by MRSA. Results: LHT-8-17 4 mg twice daily accelerated linear and planar wound healing in animals with type 1 and type 2 diabetes. The formulated topical application depressed tissue TNF-α, IL-1β, and oxidative reaction activity along with sustaining both the IL-10 concentration and antioxidant capacity. LHT-8-17 induced Ki-67 positivity of fibroblasts and pro-keratinocytes, upregulated FGFR3 gene expression, and increased tissue vascularization. The formulation possessed anti-microbial properties. Conclusions: The obtained results allow us to consider the formulation as a promising pharmacological agent for diabetic wound topical treatment.
Collapse
MESH Headings
- Administration, Topical
- Aminocaproates/administration & dosage
- Aminocaproates/metabolism
- Animals
- Cerium/administration & dosage
- Cerium/metabolism
- Diabetes Mellitus, Experimental/drug therapy
- Diabetes Mellitus, Experimental/metabolism
- Diabetes Mellitus, Experimental/pathology
- Diabetes Mellitus, Type 1/drug therapy
- Diabetes Mellitus, Type 1/metabolism
- Diabetes Mellitus, Type 1/pathology
- Diabetes Mellitus, Type 2/drug therapy
- Diabetes Mellitus, Type 2/metabolism
- Diabetes Mellitus, Type 2/pathology
- Female
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Rats
- Wound Healing/drug effects
- Wound Healing/physiology
Collapse
Affiliation(s)
- Ekaterina Blinova
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
- Department of Morphology, National Research Nuclear University MEPHI, 31 Kashirskoe Highway, 115409 Moscow, Russia
| | - Dmitry Pakhomov
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Denis Shimanovsky
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Marina Kilmyashkina
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Yan Mazov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Tatiana Demura
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Vladimir Drozdov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Dmitry Blinov
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
- Correspondence: ; Tel.: +7-927-197-1422
| | - Olga Deryabina
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Elena Samishina
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
| | - Aleksandra Butenko
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Sofia Skachilova
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
| | - Alexey Sokolov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Olga Vasilkina
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Bashar A. Alkhatatneh
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Olga Vavilova
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Andrey Sukhov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Daniil Shmatok
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Ilya Sorokvasha
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
| | - Oxana Tumutolova
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Elena Lobanova
- Department of Pharmacology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 20/1 Delegatskaya Street, 127473 Moscow, Russia;
| |
Collapse
|
2
|
Saliev T, Baiskhanova D, Beznosko D, Begimbetova D, Umbayev B, Nurgozhin T, Fakhradiyev I, Tanabayev B, Pavalkis D. A New Insight on the Radioprotective Potential of Epsilon-Aminocaproic Acid. MEDICINA (KAUNAS, LITHUANIA) 2020; 56:E663. [PMID: 33266046 PMCID: PMC7760922 DOI: 10.3390/medicina56120663] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 11/13/2020] [Accepted: 11/19/2020] [Indexed: 12/12/2022]
Abstract
Background and objectives: The aim of the study was to scrutinize the ability of epsilon-aminocaproic acid (EACA) to prevent radiation-induced damage to human cells. Materials and Methods: Human peripheral blood mononuclear cells (PBMCs) were exposed to ionizing radiation at three low doses (22.62 mGy, 45.27 mGy, and 67.88 mGy) in the presence of EACA at the concentration of 50 ng/mL. Results: EACA was able to prevent cell death induced by low-dose X-ray radiation and suppress the formation of reactive oxygen species (ROS). EACA also demonstrated a capacity to protect DNA from radiation-induced damage. The data indicated that EACA is capable of suppression of radiation-induced apoptosis. Comparative tests of antioxidative activity of EACA and a range of free radical scavengers showed an ability of EACA to effectively inhibit the generation of ROS. Conclusions: This study showed that the pretreatment of PBMCs with EACA is able to protect the cells from radiation-elicited damage, including free radicals' formation, DNA damage, and apoptosis.
Collapse
Affiliation(s)
- Timur Saliev
- S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan; (T.N.); (I.F.)
| | - Dinara Baiskhanova
- National Laboratory Astana, Nazarbayev University, Nur-Sultan 010000, Kazakhstan; (D.B.); (D.B.); (B.U.)
| | | | - Dinara Begimbetova
- National Laboratory Astana, Nazarbayev University, Nur-Sultan 010000, Kazakhstan; (D.B.); (D.B.); (B.U.)
| | - Bauyrzhan Umbayev
- National Laboratory Astana, Nazarbayev University, Nur-Sultan 010000, Kazakhstan; (D.B.); (D.B.); (B.U.)
| | - Talgat Nurgozhin
- S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan; (T.N.); (I.F.)
| | - Ildar Fakhradiyev
- S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan; (T.N.); (I.F.)
| | | | - Dainius Pavalkis
- NJSC “Astana Medical University”, Nur-sultan 010000, Kazakhstan;
| |
Collapse
|
11
|
Abstract
1. The proteolytic activities of several gamma-globulin preparations were tested. These included sulphate-precipitated human and bovine preparations and human and bovine Cohn fraction II preparations as well as purified gamma-globulin preparations. Up to 14mg. of diffusible peptides and glycopeptides/g. of gamma-globulin was liberated after dialysis and up to 10mg. of peptides/g. after incubation and trichloroacetic acid precipitation, as products of the degradation process in incubated gamma-globulin. 2. in-Aminohexanoic acid and p-chloromercuribenzoic acid, as well as heating at 60 degrees for 40min., were shown to inhibit strongly these proteolytic activities. Streptokinase was shown to activate strongly the proteolytic activity of all the human preparations (sulphate-precipitated, Cohn fraction II, and purified gamma-globulin). 3. Two distinct pH optima were shown for human and bovine gamma-globulin preparations: one at pH8, the other at pH3.8 (the latter activity could be demonstrated only in the presence of cysteine). 4. Both (131)I-labelled human Cohn fraction II and bovine fibrinogen were attacked by a sulphate-precipitated preparation of gamma-globulin. Of the synthetic substrates tested toluene-p-sulphonyl-l-arginine methyl ester was hydrolysed by both the sulphate-precipitated and Cohn fraction II preparations, as was benzoyl-l-arginine amide at pH5, but only in the presence of cysteine. 5. These data are interpreted to indicate that at least two enzymes are present in gamma-globulin preparations, one being similar to the plasmin system, the other similar to cathepsin B.
Collapse
|